Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

RCT (n=1,064) reports fingolimod 0.5mg demonstrated superior clinical efficacy vs glatiramer acetate 20mg (reduction in annualized relapse rate; 40.7% relative reduction); and had a superior benefit-risk profile compared with fingolimod 0.25mg, confirming 0.5mg to be optimal dose

JAMA Neurology